Our paper is online @atsblueeditor.bsky.social identifying plasma protein markers with HAA and correlating to new-onset fibrotic/subpleural ILA. Big thanks to our collaborators in #MESA & #SPIROMICS! www.atsjournals.org/doi/abs/10.1...

Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement @atscommunity.bsky.social #medsky 🔓 Open Access 🔗 tinyurl.com/4vjm9zdw

Current work playlist while writing. Any other music #PCCM are putting on in the background for work? @kaminskimed.bsky.social @kerrijohannson.bsky.social @ipfdoc.bsky.social @drdayjee.bsky.social @emilyfri.bsky.social @drpujamehta1.bsky.social? open.spotify.com/playlist/37i...

🧬 Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation 📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival 🔗 www.thelancet.com/journals/lan...

Delighted to share our new study evaluating the association of rare variants in telomere and non-telomere monogenic adult-onset Pulmonary Fibrosis genes and IPF patient survival where we also intersected their effects with #PRS of IPF.

Had the privilege giving a talk about early ILD detection and sharing some of the research we are doing at #KATRD annual meeting in #Gyeongju. Thank you for the opportunity and meeting so many wonderful pulmonologists.

Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social www.nature.com/articles/s41...

Excited to post my first #skySplain about our recent work published yesterday in Nature Genetics! www.nature.com/articles/s41.... One of the first authors of this study - Annika Vannan – actually wrote this breakdown, but she's not yet over here on bluesky and asked me to post!

Genomic and Serological Rheumatoid Arthritis Biomarkers, MUC5B Promoter Variant, and Interstitial Lung Abnormalities @atscommunity.bsky.social #medsky 🔗 tinyurl.com/mr4cke25

🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟 Just out in @atsblueeditor.bsky.social 🫁 www.atsjournals.org/doi/abs/10.1... State of the Art: -Epidemiology -Mechanisms of Injury -Implications - clinical & policy -Future directions

Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we? @ipfdoc.bsky.social @kaminskimed.bsky.social #CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social pmc.ncbi.nlm.nih.gov/articles/pmi...

The Blue Journal thanks Catherine L. Debban, PhD, for her contribution to the December 15 issue Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan www.atsjournals.org/doi/full/10....

Question for intensivists regarding theoretical vs observed risk tolerance. How much consideration or pause (if any) are you given when starting inhaled pulmonary vasodilators for refractory hypoxemia if the patient has concurrent left heart dysfunction? #MedSky #EMIMCC #CritCareSky #CardioSky

last night, Hallie Prescott had her NEJM review on sepsis released: www.nejm.org/doi/full/10.... Today I had the pleasure of giving some remarks on her installation as the Toews Family Legacy Professor at the University of Michigan

Using Mendelian Randomisation to identify causal associations in #IPF a 🧵

For the new BlueSky members who have left #ILDTwitter I’ve updated this starter-pack to help you find key ILD and ILD-adjacent community members here. Pls comment if I’ve missed you and I’ll add you 🫁😊 #CurePF #CureIPF #ILD go.bsky.app/8u4KcNo